Atherosclerosis  >>  Leqvio (inclisiran)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leqvio (inclisiran) / Novartis
SIRIUS, NCT05974345: In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

Completed
N/A
204691
Europe
Inclisiran sodium, Placebo, Ezetimibe, Evolocumab
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
12/23
12/23
NCT06416813: Preventive Intervention Value of Inclisiran Combined With DCB in Vulnerable Coronary Atherosclerotic Plaques

Not yet recruiting
N/A
140
NA
GDMT+DCB
Yong He
Acute Coronary Syndrome
06/27
12/27
PIILL, NCT04073797: PET Imaging of Inflammation and Lipid Lowering Study

Recruiting
N/A
63
Europe
Inclisiran, 68Ga-DOTATATE PET-MRI, Colchicine
University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Wellcome Trust, GE Healthcare, Lund University
Hypercholesterolemia, Hypercholesterolemia, Familial, Atherosclerosis, Carotid Artery Plaque
03/25
03/25
BE REAL, NCT05726838: The Belgian REAL (BE.REAL) Registry

Recruiting
N/A
300
Europe
Inclisiran
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
07/26
07/26

Download Options